Loading…
Reported covered position: Leg. Aide - Sen. Ron Wyden (D-OR)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Better Care Better Jobs Act
Client: PREMIER HOME HEALTH CARE SERVICES, INC. · Firm: VENN STRATEGIES
Issues related to home and community-based healthcare services legislation under development in the House and Senate, specifically H.R.4131 and S.2210, the Better Care Better Jobs Act.
Better Care Better Jobs Act
Client: PREMIER HOME HEALTH CARE SERVICES, INC. · Firm: VENN STRATEGIES
Issues related to home and community-based healthcare services legislation under development in the House and Senate, specifically H.R.4131 and S.2210, the Better Care Better Jobs Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
VOICES FOR NON-OPIOID CHOICES via VENN STRATEGIES
2022 · fourth_quarter · 4A
Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management.
Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| EMPLOYEE-OWNED S CORPORATIONS OF AMERICA |
| 1 |
| 2022 |
Better Care Better Jobs Act
Client: PREMIER HOME HEALTH CARE SERVICES, INC. · Firm: VENN STRATEGIES
Issues related to home and community-based healthcare services legislation under development in the House and Senate, specifically H.R.4131 and S.2210, the Better Care Better Jobs Act.
Better Care Better Jobs Act
Client: PREMIER HOME HEALTH CARE SERVICES, INC. · Firm: VENN STRATEGIES
Issues related to home and community-based healthcare services legislation under development in the House and Senate, specifically H.R.4131 and S.2210, the Better Care Better Jobs Act.
Better Care Better Jobs Act
Client: PREMIER HOME HEALTH CARE SERVICES, INC. · Firm: VENN STRATEGIES
Issues related to home and community-based healthcare services legislation under development in the House and Senate, specifically H.R.4131 and S.2210, the Better Care Better Jobs Act.
Better Care Better Jobs Act
Client: PREMIER HOME HEALTH CARE SERVICES, INC. · Firm: VENN STRATEGIES
Issues related to home and community-based healthcare services legislation under development in the House and Senate, specifically H.R.4131 and S.2210, the Better Care Better Jobs Act.
Better Care Better Jobs Act
Client: PREMIER HOME HEALTH CARE SERVICES, INC. · Firm: VENN STRATEGIES
Issues related to home and community-based healthcare services legislation under development in the House and Senate, specifically H.R.4131 and S.2210, the Better Care Better Jobs Act.
Better Care Better Jobs Act
Client: PREMIER HOME HEALTH CARE SERVICES, INC. · Firm: VENN STRATEGIES
Issues related to home and community-based healthcare services legislation under development in the House and Senate, specifically H.R.4131 and S.2210, the Better Care Better Jobs Act.
Better Care Better Jobs Act
Client: PREMIER HOME HEALTH CARE SERVICES, INC. · Firm: VENN STRATEGIES
Issues related to home and community-based healthcare services legislation under development in the House and Senate, specifically H.R.4131 and S.2210, the Better Care Better Jobs Act.
Better Care Better Jobs Act
Client: PREMIER HOME HEALTH CARE SERVICES, INC. · Firm: VENN STRATEGIES
Issues related to home and community-based healthcare services legislation under development in the House and Senate, specifically H.R.4131 and S.2210, the Better Care Better Jobs Act.
2022 · third_quarter · 3A
Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management.
Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PREMIER HOME HEALTH CARE SERVICES, INC. via VENN STRATEGIES
2022 · fourth_quarter · 4T
Issues related to home and community-based healthcare services legislation under development in the House and Senate, specifically H.R.4131 and S.2210, the Better Care Better Jobs Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PARTNERSHIP FOR PART D ACCESS via VENN STRATEGIES
2022 · fourth_quarter · Q4
Issues related to ensuring patient access to medications under the Medicare Part D program, specifically those in the six protected classes.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · fourth_quarter · Q4
Policies related to biopharmaceutical access and innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PREMIER HOME HEALTH CARE SERVICES, INC. via VENN STRATEGIES
2022 · fourth_quarter · Q4
Issues related to home and community-based healthcare services legislation under development in the House and Senate, specifically H.R.4131 and S.2210, the Better Care Better Jobs Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
VOICES FOR NON-OPIOID CHOICES via VENN STRATEGIES
2022 · fourth_quarter · Q4
Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management.
Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS, INC. via VENN STRATEGIES
2022 · fourth_quarter · 4T
Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
PARTNERSHIP FOR PART D ACCESS via VENN STRATEGIES
2022 · third_quarter · Q3
Issues related to ensuring patient access to medications under the Medicare Part D program, specifically those in the six protected classes.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · third_quarter · Q3
Policies related to biopharmaceutical access and innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS, INC. via VENN STRATEGIES
2022 · third_quarter · Q3
Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
PREMIER HOME HEALTH CARE SERVICES, INC. via VENN STRATEGIES
2022 · third_quarter · Q3
Issues related to home and community-based healthcare services legislation under development in the House and Senate, specifically H.R.4131 and S.2210, the Better Care Better Jobs Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
VOICES FOR NON-OPIOID CHOICES via VENN STRATEGIES
2022 · third_quarter · Q3
Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management.
Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMPLOYEE-OWNED S CORPORATIONS OF AMERICA via VENN STRATEGIES
2022 · third_quarter · Q3
Legislation impacting S Corporation ESOPs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARTNERSHIP FOR PART D ACCESS via VENN STRATEGIES
2022 · second_quarter · Q2
Issues related to ensuring patient access to medications under the Medicare Part D program, specifically those in the six protected classes.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · second_quarter · Q2
Policies related to biopharmaceutical access and innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS, INC. via VENN STRATEGIES
2022 · second_quarter · Q2
Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
PREMIER HOME HEALTH CARE SERVICES, INC. via VENN STRATEGIES
2022 · second_quarter · Q2
Issues related to home and community-based healthcare services legislation under development in the House and Senate, specifically H.R.4131 and S.2210, the Better Care Better Jobs Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VOICES FOR NON-OPIOID CHOICES via VENN STRATEGIES
2022 · second_quarter · Q2
Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management.
Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC. via VENN STRATEGIES
2022 · second_quarter · 2T
General issues related to the bio-pharmaceutical sector, innovation, patient access, health care manufacturing, and pandemic preparedness/response.
Measures related to U.S. international and corporate tax policy.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PARTNERSHIP FOR PART D ACCESS via VENN STRATEGIES
2022 · first_quarter · Q1
Issues related to ensuring patient access to medications under the Medicare Part D program, specifically those in the six protected classes.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · first_quarter · Q1
Policies related to biopharmaceutical access and innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS, INC. via VENN STRATEGIES
2022 · first_quarter · Q1
Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
PREMIER HOME HEALTH CARE SERVICES, INC. via VENN STRATEGIES
2022 · first_quarter · Q1
Issues related to home and community-based healthcare services legislation under development in the House and Senate, specifically H.R.4131 and S.2210, the Better Care Better Jobs Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VOICES FOR NON-OPIOID CHOICES via VENN STRATEGIES
2022 · first_quarter · Q1
Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management.
Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC. via VENN STRATEGIES
2022 · first_quarter · Q1
Measures related to U.S. international and corporate tax policy.
General issues related to the bio-pharmaceutical sector, innovation, patient access, health care manufacturing, and pandemic preparedness/response.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AVANIR PHARMACEUTICALS, INC. via VENN STRATEGIES
2021 · fourth_quarter · 4A
Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
PARTNERSHIP FOR PART D ACCESS via VENN STRATEGIES
2021 · fourth_quarter · Q4
Issues related to ensuring patient access to medications under the Medicare Part D program, specifically those in the six protected classes.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · fourth_quarter · Q4
Issues regarding FDA PDUFA procedures in COVID.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS, INC. via VENN STRATEGIES
2021 · fourth_quarter · Q4
Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
VOICES FOR NON-OPIOID CHOICES via VENN STRATEGIES
2021 · fourth_quarter · Q4
Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management.
Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC. via VENN STRATEGIES
2021 · fourth_quarter · Q4
General issues related to the bio-pharmaceutical sector, innovation, patient access, health care manufacturing, and pandemic preparedness/response.
Measures related to U.S. international and corporate tax policy.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VOICES FOR NON-OPIOID CHOICES via VENN STRATEGIES
2021 · third_quarter · Q3
Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management.
Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Q3
Issues regarding FDA PDUFA procedures in COVID.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS, INC. via VENN STRATEGIES
2021 · third_quarter · Q3
Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.
PARTNERSHIP FOR PART D ACCESS via VENN STRATEGIES
2021 · third_quarter · Q3
Issues related to ensuring patient access to medications under the Medicare Part D program, specifically those in the six protected classes.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC. via VENN STRATEGIES
2021 · third_quarter · Q3
Measures related to U.S. international and corporate tax policy.
General issues related to the bio-pharmaceutical sector, innovation, patient access, health care manufacturing, and pandemic preparedness/response.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC. via VENN STRATEGIES
2021 · second_quarter · 2A
General issues related to the bio-pharmaceutical sector, innovation, patient access, health care manufacturing, and pandemic preparedness/response.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · second_quarter · Q2
Matters related to innovation in, and patient access to, biopharmaceutical therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS, INC. via VENN STRATEGIES
2021 · second_quarter · Q2
Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.
VOICES FOR NON-OPIOID CHOICES via VENN STRATEGIES
2021 · second_quarter · Q2
Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management.
Issues relating to increasing patient and provider access to non-opioid approaches for acute pain management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARTNERSHIP FOR PART D ACCESS via VENN STRATEGIES
2021 · second_quarter · RR
Issues related to protecting access to needed medications under the Medicare Part D program, notably the six protected classes.
AVANIR PHARMACEUTICALS, INC. via VENN STRATEGIES
2021 · first_quarter · Q1
Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.
AVANIR PHARMACEUTICALS, INC. via VENN STRATEGIES
2021 · first_quarter · RR
Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.